Welcome to our dedicated page for NEONC TECHNOLOGIES HOLDINGS SEC filings (Ticker: NTHI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeOnc Technologies Holdings, Inc. (NTHI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as a Nasdaq-listed issuer focused on central nervous system therapeutics. NeOnc’s filings, including Forms 8‑K and its registration statement on Form S‑1, provide structured insight into its CNS oncology pipeline, corporate transactions and capital structure.
Through recent 8‑K filings, NeOnc has furnished press releases and supporting materials describing updated Phase 1/2a and Phase 2a clinical results for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma, including radiographic response data, progression-free survival and long-term survival metrics, as well as safety observations. Other 8‑K reports outline U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb development of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors.
Filings also detail material agreements and strategic initiatives, such as a Master Services Agreement with Insights Pharmaceutical Research LLC (IROS) to conduct multi-site clinical trials in the United Arab Emirates, the formation and role of the NuroMENA subsidiary, share exchange transactions, and acquisitions of entities like JandB Holdings, LLC. Additional disclosures cover executive appointments, equity incentive awards, bridge loans, lines of credit and other financing arrangements that support NeOnc’s clinical programs.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand key points from lengthy registration statements, 8‑K event descriptions and related exhibits, helping them interpret how clinical data updates, regulatory decisions, financing structures and governance changes may relate to NTHI’s CNS oncology strategy. Real-time updates from EDGAR ensure that new NeOnc filings are incorporated as they become available, enabling efficient review of the company’s ongoing reporting history.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reports a change in board governance. This amendment updates a prior report that announced the appointment of Nasim Shomali to the Board of Directors effective July 1, 2026. The only new disclosure is her board committee assignment.
On August 18, 2026, the Board appointed Nasim Shomali to serve as a member of the Audit Committee, effective immediately. Following this appointment, the Audit Committee consists of three directors: Bader Almonawer (Chair), Jim Delshad, and Nasim Shomali. All other aspects of the earlier report remain unchanged.
For NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI), CEO and director Thomas C. Chen, a more than ten percent owner, reported purchasing 12,757 shares of Class A common stock on 2026-08-18 at a weighted average price of $5.487 per share, with individual trades between $5.275 and $5.82 per share. The purchased shares are held indirectly in an IRA, which now holds 13,705 shares.
Chen also reports 583,531 shares held directly, and additional indirect holdings of 261,242 shares by HCWG LLC, 888,148 shares by NeuCen Biomedical Co. Ltd., 2,833,961 shares by T. R. Chen Third Family Limited Partnership, 93,253 shares by Tien Duan Chen Trust, and 948 shares by a Defined Benefit Plan. For several of these positions he disclaims beneficial ownership except to the extent of his pecuniary interest.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) director, officer and ten-percent owner Thomas C. Chen reported multiple purchases of Common Stock. On April 10 and 24, and August 14 and 17, 2026, entities associated with Chen bought an aggregate of 47,207 shares in open-market transactions at weighted average prices between about $3.85 and $5.17 per share. Certain holdings are indirect through a defined benefit plan, an IRA, HCWG LLC, NeuCen Biomedical Co. Ltd., T. R. Chen Third Family Limited Partnership, and the Tien Duan Chen Trust, with Chen disclaiming beneficial ownership beyond his pecuniary interest where noted.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported the results of its 2026 annual stockholders meeting held on August 14, 2026. Stockholders of record on June 15, 2026, holding 25,931,865 shares of common stock, were entitled to vote, and 20,208,635 shares (or 77.92%) were present, constituting a quorum.
Stockholders elected Class I directors Victoria Medvec, Ph.D. and Steven L. Giannotta, M.D. to terms ending at the 2029 annual meeting. They received approximately 16.96 million and 16.95 million "For" votes, respectively, with broker non-votes reported. Stockholders also approved an amendment to the Company’s 2023 Equity Incentive Plan, ratified the appointment of CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026, and approved the potential adjournment of the meeting if necessary to obtain a quorum or additional approvals.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported that CEO and director Thomas C. Chen, also a more-than-10% shareholder, purchased 36,259 shares of Class A common stock in open‑market or private transactions. He bought 33,787 shares at a weighted average price of $3.8477 on August 14, 2026, and 2,472 shares at $4.0445 on August 17, 2026, with actual trade prices in specified ranges. Positions reported also include indirect holdings such as 261,242 shares by HCWG LLC, 888,148 shares by NeuCen Biomedical Co. Ltd., 2,833,961 shares by T. R. Chen Third Family Limited Partnership, and 93,253 shares by the Tien Duan Chen Trust, with Chen disclaiming beneficial ownership of certain of these interests except to the extent of any pecuniary interest.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported that CEO, President and 10% owner Amir F. Heshmatpour purchased 9,000 shares of common stock on August 18, 2026 at $5.54 per share in an open-market or private transaction. Following this, he directly held 3,096,000 shares, including 275,000 shares held by certain immediate family members, for which he disclaims beneficial ownership except for any pecuniary interest. Indirect holdings reported include 256,120 shares via HCWG LLC (only his proportionate interest), 550,000 shares via KIG LLC, where his spouse is the sole member and for which he similarly disclaims beneficial ownership except for any pecuniary interest, and 3,714,020 shares via AFH Holding & Advisory, LLC, of which he is the sole member and manager.
NEONC Technologies Holdings, Inc. insider Amir F. Heshmatpour, the CEO, President and a more-than-10% holder of NTHI, reported open‑market purchases of 15,000 shares of common stock. He bought 12,000 shares on 2026-08-14 at a weighted average price of $3.7883 per share (range $3.75–$3.98) and 3,000 shares on 2026-08-17 at a weighted average price of $4.3733 per share (range $4.09–$4.94). As of 2026-08-14, he also reports indirect holdings of 256,120 shares through HCWG LLC (only his proportionate interest), 550,000 shares through KIG LLC (held by his spouse, with beneficial ownership disclaimed except for any pecuniary interest), and 3,714,020 shares through AFH Holding & Advisory, LLC, where he is sole member and manager. The filing notes that 275,000 shares are held by immediate family members, with beneficial ownership likewise disclaimed except for any pecuniary interest.
NeOnc Technologies Holdings, Inc. reported top-line results from the Phase 2a portion of its NEO100-01 trial in recurrent IDH1-mutant high-grade glioma. The single-arm study enrolled 24 patients, mostly recurrent Grade IV tumors, using intranasal delivery of NEO100 to bypass the blood–brain barrier.
The trial met its primary endpoint: progression-free survival at six months (PFS6) was 48.9%, compared with a pre-specified 20% historical benchmark, with a reported p-value of 0.0047. Median overall survival from recurrence was 26.09 months, versus a cited salvage-therapy benchmark of roughly six to nine months. Six-month overall survival was 86.7%, and 12‑month overall survival was 60.9%.
The company reported disease control (partial response plus stable disease) in 66.7% of patients and described long-term survival across combined Phase 1/2 experience, where 55% of 29 patients lived more than one year post‑recurrence. NeOnc plans to discuss a randomized Phase 3 trial with the FDA, targeting lomustine as the comparator and seeking an accelerated approval design.
NeOnc Technologies Holdings reported positive topline Phase 2a results from NEO100-01, an open-label study of intranasal NEO100 in recurrent or progressive Grade III/IV IDH1-mutant glioma after radiation and temozolomide. The study’s primary endpoint was met: six-month progression-free survival (PFS-6) was 48.9% by RANO 2.0 using Kaplan-Meier estimation (95% CI: 26.3–68.1), versus a 20% benchmark for standard care (p = 0.0047). Secondary outcomes were supportive, with median overall survival of 26.09 months from first NEO100 dose at recurrence, OS of 86.7% at six months, 60.9% at 12 months, and 54.1% at 24 months, and disease control in 66.7% of patients (8.3% partial response, 58.3% stable disease). Five of 24 patients remain on therapy, including one progression-free for about 19 months. NEO100 was administered intranasally at home four times daily and was described as generally well tolerated, with no major or dose-limiting toxicities reported. The company plans to request a Type B FDA meeting to align on a registrational development path and is outlining a proposed randomized Phase 3 trial intended to support Accelerated Approval, while emphasizing the limitations of the single-arm, 24-patient design and reliance on historical comparators.
NeOnc Technologies Holdings, Inc. reported second quarter 2026 results and highlighted progress in its CNS cancer pipeline. For the quarter ended June 30, 2026, GAAP total operating expenses were $14,069,887, including $5,651,913 of non-cash stock-based compensation, resulting in non-GAAP operating expenses of $8,417,974.
The company completed topline analysis of its fully enrolled Phase 2a NEO100 study in recurrent IDH1-mutant high-grade glioma and plans to present topline results on August 12, 2026. NeOnc also obtained UAE IND approvals for both NEO100 and NEO212, expanded clinical activities, reduced general and administrative expenses year over year, and added Nasim Shomali to its board. An investor conference call and webcast to review the NEO100 Phase 2a topline data is scheduled for August 12, 2026, at 5:30 a.m. Pacific / 8:30 a.m. Eastern.